NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levels No dose limiting toxicities have been observed Eight of nine evaluable patients with AL amyloidosis with cardiac involvement either achieved responses or were considered stable Additional Phase 1 data updates of ... (more)
http://ift.tt/1f6SUEy
http://ift.tt/1f6SUEy
No comments:
Post a Comment